Cargando…

Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis

Systemic light-chain (AL) amyloidosis is caused by a small B cell, most commonly a plasma cell (PC), clone that produces toxic light chains (LC) that cause organ dysfunction and deposits in tissues. Due to the production of amyloidogenic, misfolded LC, AL PCs display peculiar biologic features. The...

Descripción completa

Detalles Bibliográficos
Autores principales:	Palladini, Giovanni, Milani, Paolo, Malavasi, Fabio, Merlini, Giampaolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7998921/ https://www.ncbi.nlm.nih.gov/pubmed/33806310 http://dx.doi.org/10.3390/cells10030545

Ejemplares similares

Light Chain Amyloidosis
por: Milani, Paolo, et al.
Publicado: (2018)

Novel Therapies in Light Chain Amyloidosis
por: Milani, Paolo, et al.
Publicado: (2017)

Sars-Cov-2 Infection and Systemic Light Chain Amyloidosis: The International Society of Amyloidosis' Survey
por: Milani, Paolo, et al.
Publicado: (2020)

PB2151: CLINICAL FEATURES AND OUTCOMES OF DIFFUSE PULMONARY LIGHT CHAIN AMYLOIDOSIS: A RARE PRESENTATION OF SYSTEMIC AL AMYLOIDOSIS
por: Chakraborty, Rajshekhar, et al.
Publicado: (2023)

The lung in amyloidosis
por: Milani, Paolo, et al.
Publicado: (2017)

Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient
por: Swuec, Paolo, et al.
Publicado: (2019)

Mass spectrometry characterization of light chain fragmentation sites in cardiac AL amyloidosis: insights into the timing of proteolysis
por: Lavatelli, Francesca, et al.
Publicado: (2021)

Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis
por: Theodorakakou, Foteini, et al.
Publicado: (2021)

Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy
por: Milani, Paolo, et al.
Publicado: (2020)

The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018
por: Palladini, Giovanni, et al.
Publicado: (2023)

Proteotoxicity in cardiac amyloidosis: amyloidogenic light chains affect the levels of intracellular proteins in human heart cells
por: Imperlini, Esther, et al.
Publicado: (2017)

Dissecting the Molecular Features of Systemic Light Chain (AL) Amyloidosis: Contributions from Proteomics
por: Rognoni, Paola, et al.
Publicado: (2021)

DUAL expectations in light chain amyloidosis
por: Schönland, Stefan, et al.
Publicado: (2020)

Systemic light chain amyloidosis myopathy responsive to daratumumab monotherapy
por: Chitimus, Diana Maria, et al.
Publicado: (2022)

A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis
por: Sidana, Surbhi, et al.
Publicado: (2020)

Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium
por: Lousada, Isabelle, et al.
Publicado: (2015)

Role of Daratumumab in Cardiac AL Amyloidosis
por: Gertz, Morie A.
Publicado: (2022)

In situ characterization of protein aggregates in human tissues affected by light chain amyloidosis: a FTIR microspectroscopy study
por: Ami, Diletta, et al.
Publicado: (2016)

P915: EFFICACY AND SAFETY OF DARATUMUMAB MONOTHERAPY IN NEWLY DIAGNOSED PATIENTS WITH STAGE 3B LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK
por: Kastritis, E., et al.
Publicado: (2022)

Hepatic AL Amyloidosis without Significant Light Chain Elevation in a Patient Treated with CyBorD Plus Daratumumab
por: Rybinski, Brad, et al.
Publicado: (2021)

T cell landscape and dynamics in immunoglobulin light chain amyloidosis before and after daratumumab‐based therapy
por: Wang, Yujia, et al.
Publicado: (2021)

A Strategy for Synthesis of Pathogenic Human Immunoglobulin Free Light Chains in E. coli
por: Rognoni, Paola, et al.
Publicado: (2013)

Light chain (AL) amyloidosis: update on diagnosis and management
por: Rosenzweig, Michael, et al.
Publicado: (2011)

Efficacy and safety of intravenous daratumumab-based treatments for AL amyloidosis: a systematic review and meta-analysis
por: Sun, Chunyan, et al.
Publicado: (2022)

Protease‐sensitive regions in amyloid light chains: what a common pattern of fragmentation across organs suggests about aggregation
por: Mazzini, Giulia, et al.
Publicado: (2021)

AL AMYLOIDOSIS: MECHANISMS OF DISEASE AND BIOMARKERS
por: Palladini, Giovanni, et al.
Publicado: (2022)

S198: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK
por: Kastritis, Efstathios, et al.
Publicado: (2023)

Pomolidomide for relapsed/refractory light chain amyloidosis after resistance to both bortezomib and daratumumab: A case report
por: Li, Xian, et al.
Publicado: (2022)

P1714: HEALTHCARE RESOURCE UTILIZATION IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS IN EUROPE
por: Jaccard, A., et al.
Publicado: (2022)

Light Chain (AL) Amyloidosis: The Journey to Diagnosis
por: McCausland, Kristen L., et al.
Publicado: (2017)

Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial
por: Gertz, Morie A., et al.
Publicado: (2023)

Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis
por: Aimo, Alberto, et al.
Publicado: (2021)

Treatment Options For Relapsed/refractory Systemic Light-Chain (AL) Amyloidosis: Current Perspectives
por: Sarosiek, Shayna, et al.
Publicado: (2019)

Concurrent structural and biophysical traits link with immunoglobulin light chains amyloid propensity
por: Oberti, Luca, et al.
Publicado: (2017)

Proposed Cardiac End Points for Clinical Trials in Immunoglobulin Light Chain Amyloidosis: Report From the Amyloidosis Forum Cardiac Working Group
por: Maurer, Mathew S., et al.
Publicado: (2022)

Bone Marrow Microenvironment in Light-Chain Amyloidosis: In Vitro Expansion and Characterization of Mesenchymal Stromal Cells
por: Valsecchi, Chiara, et al.
Publicado: (2021)

Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through The International Kidney and Monoclonal Gammopathy Research Group
por: Havasi, Andrea, et al.
Publicado: (2022)

Physiology, Diagnosis and Treatment of Cardiac Light Chain Amyloidosis
por: Stelmach-Gołdyś, Agnieszka, et al.
Publicado: (2022)

Targeting Amyloid Fibrils by Passive Immunotherapy in Systemic Amyloidosis
por: Nuvolone, Mario, et al.
Publicado: (2022)

Improvement in Clinic Efficiency, Patient Satisfaction, and Overcoming Unique Challenges in the Era of COVID-19 with Implementation of Subcutaneous Daratumumab in Patients with Multiple Myeloma (MM) and Light Chain (AL) Amyloidosis
por: Hughes, David, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gpmfs73sbpt4vif57sql7f4k74